1	Transanal Total Mesorectal Excision for Primary Rectovaginal Carcinosarcoma: A Case
2	Report and Literature Review
3	
4	Takuto Onishi ^a , Tsukuru Amano ^b *, Toru Miyake ^c , Akiko Nakamura ^b , Yutaka Yoneoka ^b ,
5	Hiroki Nisimura ^b , Shunichiro Tsuji ^b , Masaji Tani ^c , and Takashi Murakami ^b
6	
7	^a Department of Obstetrics and Gynecology, Omihachiman Community Medical Center,
8	Tsuchidacho, Omihachiman, Shiga, 523-0082, Japan
9	
10	^b Department of Obstetrics and Gynecology, Shiga University of Medical Science, Seta, Otsu
11	520-2192, Japan
12	
13	^c Department of Surgery, Shiga University of Medical Science, Tsukinowa-cho, Seta, Otsu,
14	Shiga, 520-2192, Japan
15	
16	*Corresponding author:
17	Tsukuru Amano

18	Department of	Obstetrics and	Gynecology,	Shiga	University	of Medical	Science,	Seta,	Otsu
----	---------------	----------------	-------------	-------	------------	------------	----------	-------	------

- 19 520-2192, Japan
- 20 Tel: 077-548-2267
- 21 Fax: 077-548-2406
- 22 Email: tsukuru@belle.shiga-med.ac.jp

24 Short running title: TaTME for rectovaginal carcinosarcoma

35 Abstract

36	We report a case of rectovaginal septum carcinosarcoma successfully treated with
37	surgical excision via transanal total mesorectal excision following platinum-based
38	neoadjuvant chemotherapy. A 48-year-old woman presented with a 3-week defecation pain
39	preceding the visit. Pelvic imaging showed an 8-cm-sized lesion in the lower rectovaginal
40	septum. Transvaginal biopsy and immunohistochemical analysis were performed. After three
41	courses of carboplatin-paclitaxel-bevacizumab therapy, the mass reduced by half.
42	Subsequently, laparoscopic excision with transanal total mesorectal excision, and radical
43	hysterectomy were performed. The anus was preserved, and dysuria improved within a
44	month. The final histopathological diagnosis was carcinosarcoma of the rectovaginal septum
45	from an uncertain origin, presumably endometriotic or mesonephric. Twelve months
46	following surgery, solitary liver metastasis was confirmed; however, there was no evidence of
47	local recurrence.
48	Total mesorectal excision following platinum-based neoadjuvant chemotherapy may be an
49	ideal treatment for gynecological malignancies in the rectovaginal septum, especially for
50	large tumors localized deep into the pelvis.
51	Keywords: carcinosarcoma, neoadjuvant chemotherapy, platinum-based neoadjuvant

52 chemotherapy, rectovaginal malignancy, transanal total mesorectal.

53

54 Introduction

55	Primary malignancy of the rectovaginal septum (PMRS) is a remarkably rare
56	presentation, with the exception of gastrointestinal stromal tumors (GIST). A few cases of
57	PMRS have been described in the literature, and adjuvant chemotherapy or radiation therapy
58	following radical surgery, aimed at R0 resection has been performed. ¹⁻⁸ However, it is
59	difficult to achieve complete resection with sufficient surgical margins while preserving
60	urinary or anal function in these procedures, especially when the tumor is large and located in
61	the low rectovaginal septum.
62	Recently, transanal total mesorectal excision (TaTME) has been proposed as a technique to
63	achieve both sufficient tumor resection and functional preservation in the surgical treatment
64	of low and large rectal cancer. ^{9,10} TaTME is a technique in which an endoscope and forceps
65	are inserted through the anus, in addition to the typical abdominal approach. TaTME's
66	several benefits over laparoscopic surgery include the exposure of the distal rectum and direct
67	determination of distal resection margin. In addition, operation time can be significantly
68	reduced if two teams perform the operation simultaneously, one from the abdominal cavity

ob and the other nom the anal	69	and the	other	from	the	anus
-------------------------------	----	---------	-------	------	-----	------

70	Neoadjuvant chemotherapy (NAC) prior to definitive surgery is an alternative treatment
71	option for patients with advanced epithelial ovarian cancer. Expected benefits include
72	reduced perioperative morbidity and mortality and increased likelihood of a complete
73	resection of disease at the time of cytoreductive surgery . ^{11, 12} However, the effects of NAC
74	on PMRS remain unclear.
75	Here, we report a patient with carcinosarcoma of the rectovaginal septum who was
76	successfully treated with surgical excision using TaTME following platinum-based NAC.
77	
78	Case Report
79	The patient provided informed consent for publication of this case. A 48-year-old
80	woman (gravida 2, para 2) with a history of bilateral salpingio-oophorectomy due to pelvic
81	endometriosis presented with pain on defecation to our hospital. Upon internal examination, a
82	large mass was discovered on the back side of the posterior vaginal wall. Vaginal ultrasound
83	and magnetic resonance tomography (MRI) revealed an $80 \times 71 \times 70$ mm pelvic mass
84	suggestive of a malignant tumor of the rectovaginal septum, with no obvious distant
~ ~	

86	of the levator ani muscle on the right side (Fig. 1 C). Adenocarcinoma was detected via
87	transvaginal needle biopsy of the tumor. Immunohistochemical assessments of the tumor
88	cells for cytokeratin (CK) 7 and paired-box gene (PAX8) were positive, and those for CK 20,
89	estrogen receptor, progesterone receptor, Wilms tumor gene 1, and hepatocyte nuclear factor-
90	1 beta were negative. Serum levels of Ca125 and Ca19-9 were normal, while
91	carcinoembryonic antigen was mildly elevated (13.0 ng / mL).
92	Three courses of carboplatin-paclitaxel-bevacizumab ($CP+Bev$) therapy were administered
93	as NAC. An MRI scan following NAC revealed a clear contraction of the tumor (80 \times 71 \times
94	70 mm to $42 \times 32 \times 41$ mm) (Fig. 1 D, E). After comprehensive counselling, the patient was
95	scheduled for surgical removal using TaTME.
96	TaTME was performed by two teams: an anal approach and traditional laparoscopic teams.
97	On traditional laparoscopic inspection, no disseminated lesions were found. First, GelPOINT
98	path transanal access platform (Applied Medical, Rancho Santa Margarita, CA, USA) was
99	inserted into the pneumorectum system in the lithotomy position under general anesthesia.
100	We used the GelPOINT Path Transanal Access Platform and AirSeal (ConMed, Utica, NY,
101	USA) as insufflation systems to obtain a stable pneumorectum with smoke evacuation. The
102	lumen of the rectum was closed at the upper edge of the anal canal with a purse-string suture

104	intersphincteric resection of the muscle, and a section of the levator ani muscle on the right
105	side was excised. After the hiatal ligament was dissected, the total mesorectal excision (TME)
106	plane was revealed using a transanal approach. The traditional laparoscopic team inserted
107	five ports in parallel, and the round, infundibulopelvic, and transverse cervical ligaments
108	were separated. TME was also performed on the abdominal side. First, the trans-anal and
109	trans-abdominal layers conformed to each other on the back side, and later coincided in all
110	directions (Fig. 2B). The pelvic splanchnic nerves visceral branch of the right S3 and S4 were
111	involved in the tumor, and were resected together; however, the lower abdominal nerve, other
112	roots of the S3 and S4, and obturator nerve was preserved. The rectovaginal tumor was
113	completely excised along with the uterus, vaginal wall, and rectum via en bloc resection (Fig.
114	2C). Finally, anal canal-sigmoid anastomosis was performed and a covering ileostomy was
115	constructed (See supplement movie file). The operation took a total of 521 min, and the blood
116	loss was 500 mL. There were no intra or post-operative complications, and the patient was
117	discharged from the hospital 12 days after surgery. Initially, the patient required self-control
118	due to post-operative dysuria; however, this improved within 1 month and self-control was
119	terminated. The histopathological diagnosis was carcinosarcoma arising from the

to prevent mucus leakage (Fig. 2A). The endopelvic fascia was identified after

120	rectovaginal septum of uncertain origin, presumed to be of endometriosis or mesonephric
121	rests. The surgical margins were negative, and the patient was treated with adjuvant CP + Bev
122	therapy for three cycles and continued to receive Bev maintenance therapy following the final
123	course of CP + Bev therapy. Twelve months following surgery, solitary liver metastasis was
124	confirmed; however, there was no evidence of local recurrence. Partial liver resection and
125	closure of the ileostomy are required in the future.
126	
127	Discussion
128	To the best of our knowledge, this is the first report of PMRS successfully treated
129	with surgical excision by TaTME following platinum-based NAC. TaTME was useful in the
130	surgical resection of malignant tumors of the rectovaginal septum in this case. The
131	effectiveness of NAC for rectovaginal malignancies has not yet been established; however,
132	this case suggests that NAC should be considered to achieve both functional preservation and
133	effective resection.
134	Several cases of PMRS have been described in the literature (Table 1), excluding GIST. ^{1-8,}
135	¹³⁻¹⁷ As presented in Table 1, 13 of the 15 patients studied had adenocarcinomas. The trends
136	of CK7(+), PAX8(+), and CK20(-) indicate that the tumors were of gynecological origin, for

138	immunohistochemical results were available from these studies. Endometriosis is believed to
139	be the major developmental basis for such cancers. Seven of the 15 cases histologically
140	coexisted with endometriosis. The remaining eight were described as unrelated to
141	endometriosis; however, existing endometrial tissues and endometriomas may have been
142	destroyed by the invasion of cancer. In addition, it has been proposed that such lesions could
143	originate from mesonephric rests ¹⁸ . In the present case, the histological type of the
144	carcinosarcoma, and results of immunohistopathology were not contrary to endometriosis or
145	mesonephric rest-related malignancies ¹⁹ .
146	Primary debulking surgery, with or without adjuvant chemotherapy or irradiation, has been
147	commonly performed for gynecological PMRS (Table 1). In previous studies, patients were
148	treated with radical or preoperative (chemo) radiation therapy. Three of the patients who
149	underwent primary debulking surgery were treated laparoscopically, with the tumors
150	successfully resected. Furthermore, all three cases involved tumors of the upper rectovaginal
151	septum. In our case, as the tumor was located at the lower part of the rectovaginal septum,
152	making it difficult to secure sufficient margins and preserve the function of the pelvic organs
153	with conventional surgical methods. Therefore, TaTME was selected for radical debulking

example, from endometriosis or the mesonephric duct; however, not all

154	surgery. Moreover, as TaTME ensures an appropriate circumferential resection margin with a
155	good field of view close to the anus, a reliable distal margin and autonomic nerve
156	preservation can be achieved (mainly the pelvic splanchnic nerve S4). In our case, R0
157	resection with adequate margins was histopathologically achieved. In addition, the function
158	of the anal sphincter was preserved, and urinary dysfunction was limited to temporary and
159	clean intermittent self-catheterization, which became unnecessary approximately 1 month
160	after surgery.
161	Platinum-based neoadjuvant chemotherapy, commonly administered for ovarian cancer,
162	should also be considered for gynecological PMRS, especially when the tumor is large. The
163	characteristics of PMRS arising from endometriosis or mesonephric rests are believed to be
164	similar to those of endometriosis-associated ovarian cancers. Therefore, gynecological PMRS
165	may be treated in the same manner as ovarian cancer. Furthermore, as preoperative reduction
166	in tumor size is particularly important for rectovaginal malignancies from the anatomical
167	viewpoint, NAC should be considered. However, in the case of clear cell carcinoma, which is
168	resistant to chemotherapy, NAC should be administered with caution. Therefore, pre-
169	treatment histological examination is mandatory.

170 In conclusion, TaTME appears to be the ideal treatment for malignant tumors in the

171	rectovaginal septum, especially for large tumors localized in the deep pelvis. In addition,
172	platinum-based NAC should be considered because it may improve the performance of
173	optimal radical surgery while retaining urinary and defecatory functions. This combined
174	approach could achieve optimal oncological outcomes and functional preservation in cases of
175	rectovaginal gynecological malignancies.
176	
177•	Acknowledgements
178 179	We would like to thank Editage (www.editage.com) for English language editing.
180	Disclosure
181	There are no conflicts of interest to declare.
182	
183	References
184	[1] Ulrich U, Rhiem K, Kaminski M, et al. Parametrial and rectovaginal adenocarcinoma
185	arising from endometriosis. Int J Gynecol Cancer. 2005; 15(6): 1206–1209.
186	[2] Yang H, Gu JJ, Qi Y, Zhao W, Wang XL. Endometrioid adenocarcinoma of the rectovaginal
187	septum with invasion of the rectum: a case report and review of literature. World J Surg Oncol.

- 188 2019; 17(1): 206.
- 189 [3] Mabrouk M, Vicenzi C, Ferrini G, et al. Mixed adenocarcinoma of the rectovaginal septum
- 190 associated with endometriosis and endometrial carcinoma: a case report. Case Rep Oncol.
- 191 2011; 4(1): 149–154.
- 192 [4] Fujimoto T, Tanuma F, Otsuka N, Kataoka S. Laparoscopic posterior pelvic exenteration
- 193 for primary adenocarcinoma of the rectovaginal septum without associated endometriosis: A
- 194 case report. Mol Clin Oncol. 2019; 10(1): 92–96.
- 195 [5] Berger A, Rouzier R, Carnot F, Braunberger E, Cugnenc PH, Danel C. Primary
- 196 adenocarcinoma of the rectovaginal septum: a case report and literature review. Eur J Obstet
- 197 Gynecol Reprod Biol. 2001; 95(1): 111–113.
- 198 [6] Langmár Z, Harsányi L, Székely E, Járay B, Csömör S, Kazy Z. [Primary adenocarcinoma
- of the rectovaginal septum without associated endometriosis]. Orv Hetil. 2008; 149(47): 2251–
 200 2253.
- 201 [7] Garg G, Awonuga AO, Toy EP. Primary extrauterine endometrial stromal sarcoma: response
- to hormone therapy. Rare Tumors. 2009; 1(2): e39.
- 203 [8] Giordano G, Bersiga A, Marchetti G, Melpignano M. Primary adenocarcinoma of the
- 204 rectovaginal septum arising in pregnancy in the absence of endometriosis. Eur J Gynaecol

- 205 Oncol. 2010; 31(2): 211–213.
- 206 [9] Sylla P, Rattner DW, Delgado S, Lacy AM. NOTES transanal rectal cancer resection
- using transanal endoscopic microsurgery and laparoscopic assistance. Surg Endosc. 2010;
- 208 24(5): 1205–1210.
- 209 [10] Atallah S, Albert M, DeBeche-Adams T, Nassif G, Polavarapu H, Larach S. Transanal
- 210 minimally invasive surgery for total mesorectal excision (TAMIS-TME): a stepwise
- description of the surgical technique with video demonstration. Tech Coloproctol. 2013;
- 212 17(3): 321–325.
- [11] Onda T, Satoh T, Ogawa G, et al. Comparison of survival between primary debulking
- surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers
- in phase III randomised trial. Eur J Cancer. 2020; 130: 114–125.
- [12] Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for
- 217 newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised,
- 218 controlled, non-inferiority trial. Lancet. 2015; 386(9990): 249–257.
- [13] Papacharalabous EN, Awad SA, Edwards JL. A malignant tumour of the rectovaginal
- septum not arising from endometriosis, presenting a diagnostic enigma. J Obstet Gynaecol.
- 221 2004; 24(5): 599–600.

- 222 [14] Yazbeck C, Poncelet C, Chosidow D, Madelenat P. Primary adenocarcinoma arising
- from endometriosis of the rectovaginal septum: a case report. Int J Gynecol Cancer. 2005;
- 224 15(6): 1203–1205.
- [15] Guiou M, Hall WH, Konia T, Scudder S, Leiserowitz G, Ryu JK. Primary clear cell
- adenocarcinoma of the rectovaginal septum treated with concurrent chemoradiation therapy:
- 227 a case report. Int J Gynecol Cancer. 2008; 18(5): 1118–1121.
- [16] Songmen S, Nepal P, Fang D, Lewis E, Yagan N. Rectovaginal septum primary
- squamous cell cancer: Extremely rare entity. Radiol Case Rep. 2020; 15(4): 326–329.
- 230 [17] Kim JH, Song SH, Kim G, Kim KA, Kim WR. The multistep process of vaginal cancer
- arising from deep infiltrating endometriosis: a case report. BMC Womens Health. 2021;
- 232 21(1): 271.
- [18] Iura A, Sasajima Y, Katsumata N, Kasamatsu T. Serous adenocarcinoma of the
- retroperitoneum, as a type of multifocal müllerian carcinoma. Int J Clin Oncol. 2009; 14(3):
- 235 254–257.
- 236 [19] Amin K, Brumley B, Erickson BK, Khalifa MA. Müllerian carcinosarcoma arising from
- atypical pelvic endometriosis. Gynecol Oncol Rep. 2018; 25: 87–89.
- 238

239 **Figure Legends**

240	Figure	1
240	Figure	

- 241 T2-weighted pelvic magnetic resonance imaging. (A, B) Sagittal and axial sections show a
- 242 large mass in the rectovaginal space. (C) At the lower end, the mass extended to the right
- 243 levator ani muscle. (D, E) Similar to sections A and B. Following NAC, there was a
- significant decrease in the size of the mass (m: mass, u: uterus, v: vagina, r: rectum, red arrow
- 245 indicates the levator ani muscle).
- 246
- 247 Figure 2
- 248 (A), (B) Laparoscopic findings during TaTME. (A) The lumen of the rectum was closed at
- the upper edge of the anal canal with a purse-string suture to prevent mucus leakage. (B) The
- trans-anal and trans-abdominal layers conformed to one another at the back side (r; rectum, s;
- 251 sacrum).
- 252 (C) Operatively extracted specimen. The tumor was removed en block with the rectum,
- 253 uterus, and vagina (t; tumor, u; uterus, v; vagina, r; rectum)
- 254

256 Supporting Information: Surgical video of TaTME

- 257 TaTME was performed by two teams: an anal approach and traditional laparoscopic teams.
- 258 The rectovaginal tumor was completely excised along with the uterus, vaginal wall, and
- 259 rectum via en bloc resection. Anal sphincter and urinary function was preserved.





Case	Reference, year	Age	Histological type	Immunohistopathology	Endometriosis	Treatment	Follow-up
1	Berger et al. [3], 2001	58	Adenocarcinoma	NA	-	AH+BSO+RR⇒RT	RE 5 years later
2	Papacharalabous et al. [13], 2004	57	Adenocarcinoma	NA	-	AH + BSO + RR	NED12months
3	Ulrich et al. [1], 2005	41	Adenocarcinoma	NA	+	RR+BSO+LN⇒RT	NED 2 years
4	Ulrich et al. [1], 2006	51	Adenocarcinoma	NA	+	BSO+LN+vagina, paracolpium	RE 2 years later
						resection + RR \Rightarrow RT	
5	Yazbeck et al. [14], 2005	25	Adenocarcinoma	CK7(+), CK20(-)	+	$CRT \Rightarrow AH+OM+LN+RR$	NED 2 years
6	Guiou et al. [15], 2008	52	Clear cell adenocarcinoma	CK7(+)	-	CRT	NED
7	Langmár et al. [6], 2008	68	Adenocarcinoma	NA	-	TAH+BSO+RR⇒CT	N/A
8	Garg et al. [7], 2009	45	Endometrial stromal sarcoma	NA	+	PE⇒RT	N/A
9	Giordano et al. [8], 2010	37	Adenocarcinoma	CK7(+), CA125(+)	-	TAH+BSO+RR⇒CT	N/A
10	Mabrouk et al. [3], 2011	36	Mixed (clear cell and	CK7(+), ER (+)	+	LRH+BSO+LN+OM+RR⇒CT	NED 2 months
			endometrioid) adenocarcinoma				
11	Fujimoto et al. [4], 2019	49	Adenocarcinoma	CK7(+), ER (+), CK20(-)	-	$LH+BSO+RR+LN + vaginectomy \Rightarrow$	DOD 14 months
						СТ	
12	Yang et al. [2], 2019	57	Endometrioid carcinoma	CK7(+), ER (+),	+	RH+BSO+LN+OM+AP+RR⇒CT	NED 6 months
				PAX-8(+), CK20(-)			
13	Songmen et al. [16], 2020	35	Squamous cell carcinoma	NA	-	CRT	NED 4 months
14	Kim et al. [17], 2021	40	Endometrioid carcinoma	NA	+	L-RH+RR	NED 8 months
15	present case	48	Carcinosarcoma	CK7(+), ER (+), PAX-8(+),	-	NAC⇒TaTME⇒CT	NED 12months
				CK20(-)			

Table 1. Characteristics of previously reported patients with gynecological-related rectal-vaginal septal tumor in past 20 years.

AH; abdominal hysterectomy; BSO = bilateral salpingo-oophorectomy RR = rectal resection RT; irradiation therapy LN; lymphadenectomy CRT; chemoradiation therapy OM; omentectomy CT; chemotherapy PE; pelvic exenteration L-; laparoscopic RH; radical hysterectomy LH; laparoscopic hysterectomy AP; appendectomy NA = not available